[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495574":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":48,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"University Hospital, Toulouse","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Resected early stage non small cell lung cancer",null,"Early stage (IA-IIIA) resectable non small cell lung cancer patients receiving surgery",[13],"Other: Resected non small cell lung cancer",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Resected non small cell lung cancer","plasma sample, tissue sample and computed tomography scan images",[9],[20],{"name":21,"affiliation":5,"role":22},"Julien MAZIERES, MD, PhD","PRINCIPAL_INVESTIGATOR",[24],{"name":21,"role":25,"phone":26,"phoneExt":27,"email":28},"CONTACT","0567771837","33","mazieres.j@chu-toulouse.fr",[30],{"facility":31,"status":32,"city":33,"state":10,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Julien MAZIERES","RECRUITING","Toulouse","31059","France","FR",{"type":38,"coordinates":39},"Point",[40,41],1.44367,43.60426,{"lat":41,"lon":40},[44,45],{"name":31,"role":25,"phone":26,"phoneExt":10,"email":28},{"name":46,"role":25,"phone":10,"phoneExt":10,"email":47},"Julie MILIA","milia.j@chu-toulouse.fr",{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100495574","a-machine-learning-approach-to-identify-patients-with-resected-non-small-cell-lung-cancer-with-high-risk-of-relapse-100495574",false,"NCT05732974","A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse","MIRACLE","Inclusion Criteria:\n\n* Patient with an early stage of non small cell lung cancer\n* Indication of surgical resection\n* Patient able to understand and give his consent\n* Patient affiliated to the health insurance\n\nExclusion Criteria:\n\n* Patient with another cancer in the last 5 years\n* Patient with an allergy to the contrast medium\n* Patient under legal protection","ALL","18 Years",{"count":60,"type":61},60,"ESTIMATED","OBSERVATIONAL","Early-stage non small cell lung cancer represents 20-30% of all non small cell lung cancer and is characterized by a high survival probability after surgical resection. However, considering stage IA-IIIA non small cell lung cancer, a relapse rate of about 50% is observed, with a different survival probability on the basis of tumor node metastasis status, although patients within the same tumor node metastasis stage exhibit wide variations in recurrence rate. There are currently no validated prognostic biomarkers able to identify patients with a high risk of relapse.",[65],"Non-small Cell Lung Cancer Stage IIIA",[67,68],"Machine-learning","Resected early stage Non-small Cell Lung Cancer","2023-09-18",{"date":71,"type":72},"2023-09-21","ACTUAL",{"date":74,"type":72},"2023-03-30",{"date":76,"type":61},"2026-10-30",{"name":5,"class":6},1]